Search: id:"swepub:oai:DiVA.org:liu-49949" >
Long-term follow-up...
Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy
-
- Wilking, N. (author)
- Department of Oncology, Karolinska Institutet, Stockholm, Sweden, Radiumhemmet Karolinska Hospital, Stockholm, Sweden
-
- Lidbrink, E. (author)
- Radiumhemmet, Karolinska Institutet and University Hospital, Solna, S-171 76 Stockholm, Sweden
-
- Wiklund, T. (author)
- Roche OY, Espoo, Finland, Department of Oncology, University Hospital, Helsinki, Finland
-
show more...
-
- Erikstein, B. (author)
- Southern Norway Regional Health Authority, Skien, Norway, The Norwegian Radiumhospital, Oslo, Norway
-
- Lindman, Henrik (author)
- Uppsala universitet,Institutionen för onkologi, radiologi och klinisk immunologi,Department of Oncology, Akademiska Hospital, Uppsala, Sweden
-
- Malmström, Per (author)
- Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Malmström, P., Department of Oncology, University Hospital, Lund, Sweden
-
- Kellokumpu-Lehtinen, P. (author)
- Department of Oncology, Tampere University, University Hospital, Tampere, Finland
-
- Bengtsson, N.-O. (author)
- Umeå universitet,Institutionen för strålningsvetenskaper,Department of Oncology, University Hospital, Umeå, Sweden,Department of Oncology, Ryhov Hospital, Jönköping, Sweden
-
- Söderlund, G. (author)
- Östergötlands Läns Landsting,Onkologiska kliniken US
-
- Anker, G. (author)
- Department of Oncology, Haukeland University Hospital, Bergen, Norway, Department of Oncology, Haukeland Hospital, Bergen, Norway,Department of Hematology, Karolinska Hospital, Stockholm, Sweden,Department of Oncology, Gävle Hospital, Gävle, Sweden
-
- Wist, E. (author)
- Department of Oncology, Ullevål University Hospital and Faculty of Medicine, University of Oslo, Oslo, Norway, Department of Oncology, Regional Hospital, Tromsø, Norway
-
- Ottosson, S. (author)
- Department of Oncology, NÄL, Trollhättan, Sweden,Department of Oncology, Sahlgrenska Hospital, Göteborg, Sweden
-
- Salminen, E. (author)
- Department of Oncology, Turku University Hospital, Turku, Finland
-
- Ljungman, P. (author)
- Karolinska Institutet,Haematology Centre, Karolinska University Hospital, Stockholm, Sweden, Department of Hematology, Huddinge Hospital, Stockholm, Sweden
-
- Holte, H. (author)
- Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway, Hematology Section, The Norwegian Radiumhospital, Oslo, Norway,Mälarsjukhuset Eskilstuna of Oncology, Borås Hospital, Borås, Sweden,Department of Oncology, Ullevål Hospital, Oslo, Norway
-
- Nilsson, J. (author)
- Trial Form Support AB, Stockholm, Sweden
-
- Blomqvist, C. (author)
- Department of Oncology, University Hospital, Helsinki, Finland
-
- Bergh, J. (author)
- Karolinska Institutet,Department of Oncology, Karolinska Institutet, Stockholm, Sweden, Radiumhemmet, Karolinska Institutet and University Hospital, Solna, S-171 76 Stockholm, Sweden, Radiumhemmet Karolinska Hospital, Stockholm, Sweden
-
- Hoglund, M. (author)
- Höglund, M., Department of Hematology, University Hospital, Uppsala, Sweden
-
- Bengtsson, M. (author)
- Department of Clinical Immunology, University Hospital, Uppsala, Sweden
-
- Gruber, A. (author)
- Department of Hematology, Karolinska Hospital, Stockholm, Sweden
-
- Fornander, T. (author)
- Department of Oncology, Södersjukhuset,, Stockholm, Sweden
-
- Petterson-Skold, D. (author)
- Petterson-Sköld, D., Department of Oncology, Danderyd Hospital, Stockholm, Sweden
-
- Lofvenberg, E. (author)
- Löfvenberg, E., Department of Hematology, University Hospital, Umeå, Sweden
-
- Villman, K. (author)
- Department of Oncology, Örebro Hospital, Örebro, Sweden
-
- Karlsson, Katarina (author)
- Linköpings universitet,Hälsouniversitetet,Omvårdnad,Department of Internal Medicine, University Hospital, Turku, Finland
-
- Hultborn, R. (author)
- Department of Oncology, Sahlgrenska Hospital, Göteborg, Sweden
-
- Ottoson, S. (author)
- Department of Oncology, Sahlgrenska Hospital, Göteborg, Sweden
-
- Mattson, J. (author)
- Department of Surgery, Sahlgrenska Hospital, Göteborg, Sweden,Department of Hematology, Ullevål Hospital, Oslo, Norway
-
- Jansson, S. (author)
- Department of Surgery, Sahlgrenska Hospital, Göteborg, Sweden
-
- Braide, I. (author)
- Department of Hematology, Sahlgrenska Hospital, Göteborg, Sweden
-
- Carlsson, G. (author)
- Department of Oncology, Östra Hospital, Göteborg, Sweden
-
- Rodjer, S. (author)
- Rödjer, S., Department of Hematology, Östra Hospital, Göteborg, Sweden
-
- Sallerfors, B. (author)
- Department of Hematology, University Hospital, Lund, Sweden
-
- Ahlgren, J. (author)
- Department of Oncology, Gävle Hospital, Gävle, Sweden
-
- Gawelin, A. (author)
- Department of Oncology, Gävle Hospital, Gävle, Sweden
-
- Solderberg, M. (author)
- Sölderberg, M., Department of Oncology, Karlstad Hospital, Karlstad, Sweden
-
- Hansen, J. (author)
- Department of Oncology, Västerås Hospital, Västerås, Sweden
-
- Stenstam, B. (author)
- Department of Oncology, Mälarsjukhuset, Eskilstuna, Sweden
-
- Svensson, J.-H. (author)
- Mälarsjukhuset Eskilstuna of Oncology, Borås Hospital, Borås, Sweden
-
- Norberg, B. (author)
- Department of Oncology, Ryhov Hospital, Jönköping, Sweden
-
- Kvalheim, G. (author)
- Department of Medicine, The Norwegian Radiumhospital, Oslo, Norway
-
- Sommer, H.H. (author)
- Department of Oncology, Ullevål Hospital, Oslo, Norway
-
- Tangen, J.M. (author)
- Department of Hematology, Ullevål Hospital, Oslo, Norway
-
- Lundgren, S. (author)
- Department of Oncology, Regional Hospital, Trondheim, Norway
-
- Remes, K. (author)
- Department of Internal Medicine, University Hospital, Turku, Finland
-
- Lehtinen, M. (author)
- Department of Clinical Chemistry, Division of Hematology, University Hospital, Tampere, Finland
-
- Koivinen, E. (author)
- Department of Clinical Chemistry, Division of Hematology, University Hospital, Tampere, Finland
-
- Turpeenniemi-Hujanen, T. (author)
- Department of Oncology, Oulu University Hospital, Oulu, Finland
-
- Kuittinen, O. (author)
- Department of Oncology, Oulu University Hospital, Oulu, Finland
-
- Voutilainen, L. (author)
- Department of Oncology, Kuopio University Hospital, Kuopio, Finland
-
- Mirza, M.R. (author)
- Department of Oncology, University Hospital, Odense, Denmark
-
- Rose, C. (author)
- Department of Oncology, University Hospital, Odense, Denmark
-
show less...
-
(creator_code:org_t)
- Elsevier BV, 2007
- 2007
- English.
-
In: Annals of Oncology. - : Elsevier BV. - 0923-7534 .- 1569-8041. ; 18:4, s. 694-700
- Related links:
-
https://doi.org/10.1...
-
show more...
-
http://dx.doi.org/10... (free)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
https://urn.kb.se/re...
-
http://kipublication...
-
https://lup.lub.lu.s...
-
show less...
Abstract
Subject headings
Close
- Background: The purpose was to investigate adjuvant marrow-supportive high-dose chemotherapy compared with an equitoxicity-tailored comparator arm. Patients and methods: Five hundred and twenty-five women below theage of 60 years with operated high-risk primary breast cancer were randomised to nine cycles of granulocyte colony-stimulating factor supported and individually tailored FEC (5-fluorouracil, epirubicin, cyclophosphamide), (n = 251) or standard FEC followed by marrow-supported high-dose therapy with CTCb (cyclophosphamide, thiotepa, carboplatin) therapy (n = 274), followed by locoregional radiotherapy and tamoxifen for 5 years. Results: There were 104 breast cancer relapses in the tailored FEC group versus 139 in the CTCb group (double triangular method by Whitehead, P = 0.046), with a median follow-up of all included patients of 60.8 months. The event-free survival demonstrated 121 and 150 events in the tailored FEC- and CTCb group, respectively [P = 0.074, hazard ratio (HR) 0.804, 95% confidence interval (CI) 0.633-1.022]. Ten patients in the tailored FEC regimen developed acute myeloid leukaemia (AML)/myelodysplasia (MDS). One hundred deaths occurred in the tailored FEC group and 121 in the CTCb group (P = 0.287, HR 0.866, 95% CI 0.665-1.129). Conclusion: The update of this study shows an improved outcome linked to the tailored FEC treatment in relation to breast cancer relapse, but also an increased incidence of AML/MDS. © 2007 Oxford University Press.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Keyword
- Adjuvant
- Breast cancer
- Randomised
- Tailored chemotherapy
- MEDICINE
- MEDICIN
- adjuvant
- tailored chemotherapy
- randomised
- breast cancer
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Wilking, N.
-
Lidbrink, E.
-
Wiklund, T.
-
Erikstein, B.
-
Lindman, Henrik
-
Malmström, Per
-
show more...
-
Kellokumpu-Lehti ...
-
Bengtsson, N.-O.
-
Söderlund, G.
-
Anker, G.
-
Wist, E.
-
Ottosson, S.
-
Salminen, E.
-
Ljungman, P.
-
Holte, H.
-
Nilsson, J.
-
Blomqvist, C.
-
Bergh, J.
-
Hoglund, M.
-
Bengtsson, M.
-
Gruber, A.
-
Fornander, T.
-
Petterson-Skold, ...
-
Lofvenberg, E.
-
Villman, K.
-
Karlsson, Katari ...
-
Hultborn, R.
-
Ottoson, S.
-
Mattson, J.
-
Jansson, S.
-
Braide, I.
-
Carlsson, G.
-
Rodjer, S.
-
Sallerfors, B.
-
Ahlgren, J.
-
Gawelin, A.
-
Solderberg, M.
-
Hansen, J.
-
Stenstam, B.
-
Svensson, J.-H.
-
Norberg, B.
-
Kvalheim, G.
-
Sommer, H.H.
-
Tangen, J.M.
-
Lundgren, S.
-
Remes, K.
-
Lehtinen, M.
-
Koivinen, E.
-
Turpeenniemi-Huj ...
-
Kuittinen, O.
-
Voutilainen, L.
-
Mirza, M.R.
-
Rose, C.
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cancer and Oncol ...
- Articles in the publication
-
Annals of Oncolo ...
- By the university
-
Linköping University
-
Umeå University
-
Uppsala University
-
Karolinska Institutet
-
Lund University